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Abstract To estimate the effect of tobacco smoking on iron
homeostasis and the possible association between hepcidin
and the neonatal birth weight and length, concentrations of
serum hepcidin and selected iron markers were measured in
81 healthy pregnant women (41 smokers and 40 nonsmokers).
The smoking mothers had significantly lower concentrations
of serum hepcidin (p < 0.001), iron (p < 0.001), and hemoglo-
bin (p < 0.05), but higher erythropoietin (p < 0.05) levels
compared with non-smoking pregnant women. Logistic re-
gression analysis showed the highest negative impact of the
number of cigarettes smoked per day (β = −0.46; p < 0.01) and
positive impact of ferritin level (β = 0.47; p < 0.001) on serum
hepcidin concentration. The birth weight and the body length
of smoking mothers’ infants were significantly lower than in
tobacco abstinent group (p < 0.001). In multiple regression
analysis, birth body weight (β = 0.56; p < 0.001) and length
(β = 0.50; p < 0.001) were significantly related to maternal
hepcidin values. Tobacco smoking affected hepcidin level in
serum of pregnant women in a dose-dependent manner. Low
concentrations of iron and hemoglobin in maternal serum
coexisting with high level of erythropoietin suggest that
smoking could lead to subclinical iron deficiency and chronic
hypoxia not only in mothers but also in fetus. Low serum
hepcidin concentration in smoking pregnant women might
be associated with lower fetal birth weight and length.
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Introduction
Iron deficiency during pregnancy continues to be a common
clinical problem and is one of the most prevalent nutritional
deficits both in the industrial and developing countries. Iron
requirements increase significantly (near 10-fold) over gesta-
tion; therefore, pregnant women are particularly at risk of
developing iron deficiency anemia. The prevalence of anemia
is dependent on nutritional status and use of sufficient prenatal
supplements and ranges from 14 to 52 % women who are not
taking prenatal supplements, to 0–25 % among pregnant
women receiving regular multivitamin (containing iron and
folic acid) preparation [1–5].
In the last decade, much attention was paid to research on
newmarkers involved in the regulation of iron homeostasis [4,
6]. Hepcidin, a 25-amino-acids peptide hormone (Hep-25),
has recently emerged as a key regulator of iron homeostasis.
Apart from main synthesis in the liver, hepcidin messenger
RNA (mRNA) is also expressed in the lung, heart, brain,
and placenta tissue. Hepcidin regulates intestinal absorption,
macrophage release, and the placental passage of iron. This
hormone inhibits the cellular efflux of iron by binding to and
inducing the degradation of ferroportin, the only known cel-
lular iron exporter [7]. The role of hepcidin in the regulation of
iron metabolism in pregnancy and its effects on the fetus and
consequently on the newborn is not fully understood. Rising
iron requirements in subsequent trimesters of pregnancy, in
both the mother and the fetus, induces an increase in maternal
dietary iron absorption and increase iron flux to the fetus via
placenta [1, 2]. In utero-placenta unit, hepcidin causing deg-
radation of syncytiotrophoblast ferroportin regulates iron
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release into the fetal circulation [8, 9]. Hepcidin expression is
induced by iron overload and inflammation and is suppressed
by anemia, erythropoietic activity, and hypoxia [10, 11]. Iron
deficiency in pregnant women is assumed to be enhanced by
cigarette smoking [12, 13]. Despite the fact that in the last
years, a decrease in the number of active smokers has been
observed and knowledge of the adverse health effect of
smoking during pregnancy is quite common, 25–30 % preg-
nant women in Poland continue smoking [14, 15]. Tobacco
smoking is associated in dose-related manner with stimulation
of erythropoiesis due to increased maternal and fetal iron re-
quirements probably through a hypoxic effect [16–18]. It is
suggested that accompanying smoking hypoxia can suppress
hepcidin mRNA expression and reduces hepcidin concentra-
tion in pregnant women as well as in newborns.
The aim of the study was to estimate the effect of tobacco
smoking on serum hepcidin and selected iron parameters in
pregnant women. We evaluated relationships between
hepcidin and other indicators of iron status. Furthermore, we
investigated the possible association between serum hepcidin
concentration and the neonatal birth weight and length.
Methods
Patients
Two groups of women were taken from a prospective obser-
vational study for adverse effects of tobacco smoking in preg-
nant women visiting the Department of Obstetrics and Gyne-
cology, Institute of Mother and Child, Warsaw, Poland, be-
tween January 2013 andMarch 2015. The study was conduct-
ed according to the principles of the Declaration of Helsinki
and was approved by the Ethics Committee of the Institute of
Mother and Child. All pregnant volunteers were made aware
of the study objectives and informed written consent was ob-
tained for analysis of biological samples and linking results to
the data collected from questionnaires.
The base study population, wherein the present study was
nested, constituted 296 singleton pregnancies. In the study
group, 41 cases were included which had hospital visits in
the third trimester of pregnancy (32–36 weeks) and continued
smoking during pregnancy (minimum five cigarettes per day
and minimum 2 years before conception). The control group
consisted of 40 non-smoking, healthy pregnant women simi-
lar to age and gestational age. Gestational age was estimated
by the last menstrual period and confirmed or corrected by
ultrasonographic measurements of the crown-rump length
(dated in the first trimester). The groups included only women
with a single physiological pregnancy who, before pregnancy,
had normal menstrual cycles, were in good health at time of
examination, and declared good living conditions. The exclu-
sion criteria for the study were maternal diseases
(preeclampsia, hypertension, diabetes mellitus, active hepati-
tis, renal and cardiovascular diseases, and inflammatory con-
ditions), multiple pregnancy, birth defects detected during
pregnancy, alcohol drinking, and assisted reproduction. Wom-
en exposed to second-hand smoke (smoking spouse or other
family members, co-workers) were excluded from the tobacco
abstinent group. The classification of groups was confirmed
by measurement of serum cotinine- the major metabolite of
nicotine in pregnant women. A cutoff value of ≥13.7 μg/L
was used to separate smokers from nonsmokers, in accor-
dance with others studies [19]. All subjects in our study re-
ported taking standard vitamins with iron and folate during
pregnancy (average 400–800 μg of folate, 15–60 mg of fer-
rous fumarate daily).
After birth, clinical information on the infants, including
weight and body length, were collected.
Collection and Analysis of Blood Samples
Maternal peripheral blood samples (5 mL) were taken at the
time of recruitment (30–34 weeks of gestation). In order to
obtain serum, the blood was centrifuge at 2500×g at 4 °C for
10 min and was stored in small portions at −25 °C for subse-
quent biochemical analysis.
Serum hepcidin, erythropoietin (EPO), and soluble trans-
ferrin receptor (sTfR) values were determined by immunoas-
say (DRG, Marburg Mediagnost, Reutlingen, Germany). The
limit of detection was 0.35 ng/mL for hepcidin, 1.1 mIU/mL
for EPO, and 2 ng/mL for sTfR, respectively. The intra- and
inter-assay coefficients of variation were less than 3.3 and
11.5 % for hepcidin, 8.4 and 8.8 % for EPO, and 6.0 and
7.0 % for sTfR, respectively.
Serum levels of iron (Fe), ferritin (Ft), transferrin (Tf), and
C-reactive protein (CRP) were measured by standard methods
using commercially available kits on COBAS INTEGRA an-
alyzer (Roche, Switzerland). Concentration of hemoglobin
(Hgb) in blood was determined using commercially available
kits on Pentra 60 hematology analyzer (HORRIBA ABX,
France).
Co t in ine l eve l s in se rum were eva lua t ed by
immunoenzymatic method using a commercially available
kit Cotinine one-step ELISA (Calbiotech Inc., Spring Valley,
CA, USA).
Pre-pregnancy body mass index (BMI) was calculated
using height and pre-pregnancy weight. Newborn infants were
examined in the first 24 h of life. Neonatal length and weight
were determined using a measuring board to the nearest
0.1 cm and a calibrated scale to the nearest 10 g.
Statistical Analysis
Statistical analysis was performed using STATISTICA 10.0
(StatSoft, Poland) software. Data were presented as mean
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values and standard deviation (SD) for normal distribution or
median value and interquartile range (25th–75th percentiles)
for skewed distribution. The Shapiro-Wilk test was used for
evaluation normality of data distribution prior to statistical
analysis. Group differences were determined by Student’s t
test or Mann-Whitney test depending on the assumptions.
The chi-square test was used for comparing nominal variables.
For simple correlation analysis, Pearson or Spearman correla-
tion coefficients were calculated. Linear regression models
with concentration of hepcidin as a dependent variable were
estimated in the separate sample of smokers to examine the
potential impact of some iron parameters, number of the cig-
arettes per day, and cotinine level. To evaluate relationships
between anthropometric parameters and studied iron markers,
multivariate linear regression models with body birth weight
and body birth length as dependent variables were estimated
(adjusted for gender and smoking status).
Results were expressed as the value of β standardized re-
gression coefficient and its significance together with coeffi-
cient of determination R-squared expressed as the percent of
the variation that can be explained by regression equation. A p
value less than 0.05 was considered statistically significant.
Results
Table 1 presents the clinical characteristics and bio-
chemical measurements of the 81 participants who com-
pleted the study. Maternal clinical characteristics param-
eters were comparable in both groups except for ciga-
rette smoking habits. In the group of smoking mothers,
the mean number of cigarettes per day was 8.8, the
mean duration of smoking before conception was
8.6 years, and the mean serum cotinine concentration
was 86.5 μg/L. In the tobacco abstinent group, serum
cotinine was present only in trace amounts. There were
no severe complications during delivery in either group.
Mean birth weight, body length, and head circumference
of the smoking mothers’ infants were significantly lower
(p < 0.001; p < 0.01; p < 0.001, respectively) compared
with that of the abstinent group. Apgar score was sim-
ilar in the two groups. According to biochemical
markers, the smoking mothers had significantly lower
concentrations of serum hepcidin (p < 0.001), iron
(p < 0.01), and hemoglobin (p < 0.05), but higher
erythropoietin levels (p < 0.05) compared with non-
smoking pregnant women. The levels of ferritin, soluble
transferrin receptor, and C-reactive protein were similar
in both groups.
In smoking pregnant women group, hepcidin was negative-
ly related to the number of cigarettes per day (p < 0.01), co-
tinine (p < 0.05), EPO (p < 0.05), and sTfR (p < 0.05) in linear
regression analysis. On the contrary, hepcidin was positively
related to Ft (p < 0.001) and Hgb (p < 0.05). We did not
observe significant correlations between hepcidin and iron as
well as transferrin. Hepcidin was not related to C-
reactive protein—marker of acute phase inflammation
(Table 2).
Correlation studies revealed that birth weight and birth
length in infants of smokers were negatively related with se-
rum cotinine and number of cigarettes smoked per day. The
relationship between hepcidin concentration and anthropo-
metric parameters was observed in both groups. Additionally,
birth body weight was positively correlated with iron and
hemoglobin levels only in the group of tobacco abstinent,
whereas birth body length correlated negatively with erythro-
poietin only in the smoking group (Table 3).
In multi-variable regression model defined for the whole
group, adjusted for gender and smoking status, birth body
weight was associated with serum hepcidin (β = 0.559,
p = 0.000) and iron (β = 0.240, p = 0.008) but not hemoglobin
(β = −0.105, p = 0.314). For birth body length, the highest
impact of the serum hepcidin concentration was indicated
(β = 0.496, p = 0.000). Markers of estimated intensity of
cigarette smoking and ferritin concentration were not included
in the same multi-variable model because these parameters
and hepcidin were highly dependent (R2 = 21.5 % for number
of cigarettes per day, R2 = 14.5 % for cotinine, R2 = 22.5 % for
ferritin).
Discussion
Research on the relationship between smoking during
pregnancy and total body iron stores has been conduct-
ed for many years, but corresponding literature data are
still fragmentary and the results are controversial. No
effect of smoking on iron homeostasis parameters dur-
ing gestation was reported; however, some investigators
observed a tendency to decrease concentrations of he-
moglobin, hematocrite, and iron with longer smoke ex-
position and more cigarettes smoked per day [12, 15,
20, 21]. Our findings showed that hemoglobin and iron
levels were significantly lower in the smoking group
than in the tobacco abstinent. The same results were
described by Rasmussen et al. [13] and Zafar et al.
[22] who suggested that iron supplementation through
pregnancy had a higher relative increase in hemoglobin
concentration toward the end of pregnancy. In the case
of transferrin, soluble transferrin receptor, and ferritin
concentrations, we did not identify differences between
the studied groups. This is consistent with other’s pre-
vious research where no significant relation between
concentration of ferritin and smoking was found [13].
On the contrary, some studies showed higher levels of
ferritin in pregnant women who smoke [18, 23]. This
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may be due to the fact that they have been conducted
in group of women between 19 and 26 weeks of ges-
tation, while iron deficiency is the highest at the end of
pregnancy [23].
There are a few human studies assessing hepcidin during
pregnancy [2, 24–31]. Concentration of this hormone in
healthy non-smoking pregnant women decreased gradually
in the course of pregnancy in order to maximize iron absorp-
tion and availability, thus enhancing transfer to the fetus [4,
26–29]. The third trimester values of hepcidin in our study are
consistent with the report by Rehu et al. [30] and Young et al.
[26] and slightly higher than the report by other investigators
[24, 25, 31]. These differences may result from the method
applied with hepcidin, selection of the research group, mate-
rial, gestational age, and type of delivery. Some authors pos-
tulated elevated hepcidin at the day of delivery and in women
who delivered vaginally in comparison to cesarean section
which may be related to inflammatory cytokine activation
during labor and the postpartum period [26, 30, 32]. In gener-
al, for uncomplicated pregnancies, no relation between
Table 1 Clinical characteristics
and biochemical measurements in
smoking and non-smoking
pregnant women (n = 81)
Characteristic Smoking (n = 41) Non-smoking (n = 40) p value
Maternal age (years)a 28.8 ± 4.5 30.3 ± 4.8 0.120
Ethnic origin: Caucasian (%)c 100 100 –
Maternal weight (kg)a 63.9 ± 5.2 65.6 ± 5.4 0.123
Maternal height (cm)a 165.1 ± 0.1 165.0 ± 0.1 0.884
Pre-gravid BMI (kg/m2)a 23.4 ± 1.3 24.1 ± 1.4 0.073
Gestational age of delivery (weeks)b 39 [39–40] 39 [39–40] 0.384
Delivery: cesarean/vaginal (%)c 4.9/95.1 2.5/97.5 0.571
Neonatal gender female/male (%)c 46/54 38/62 0.420
Birth weight (g)a
Whole group 3123.7 ± 426.4 3516.6 ± 445.6 0.000
Male 3160.5 ± 388.7 3647.2 ± 399.2 0.000
Female 3081.1 ± 473.6 3298.7 ± 445.6 0.182
Birth body length (cm)a
Whole group 54.4 ± 2.7 55.9 ± 2.5 0.009
Male 54.6 ± 3.0 56.6 ± 2.4 0.010
Female 54.1 ± 3.0 54.8 ± 2.3 0.431
Head circumference (cm)a
Whole group 34.0 ± 1.7 35.0 ± 1.1 0.000
Male 34.3 ± 1.1 35.2 ± 1.0 0.003
Female 33.7 ± 1.3 34.7 ± 1.1 0.033
Apgar score (5th min)b 10 [10–10] 10 [10–10] 0.576
Number of cigarettes/dayb 10 [5–10] 0 –
Time of smoking before conception (year)b 8 [5–12] 0 –
Cotinine (μg/L)b 87.9 [58.1–108.5] 0 –
Hepcidin (ng/mL)a 10.9 ± 6.8 16.3 ± 6.8 0.000
EPO (mIU/mL)b 17.6 [12.5–32.7] 14.4 [12.2–21.3] 0.037
Ft (ng/mL)b 11.5 [8.5–15.7] 13.5 [8.8–30.4] 0.170
Fe (μmol/L)a 12.0 ± 4.5 16.4 ± 7.0 0.001
Hgb (g/dL)a 12.2 ± 1.1 12.7 ± 1.1 0.049
sTfR (μg/mL)b 1.3 [1.2–1.7] 1.1 [1.0–1.6] 0.161
Tf (mg/dL)a 417.7 ± 65.1 400.1 ± 82.1 0.208
CRP (nmol/L)a 59.0 ± 17.1 56.2 ± 16.2 0.549
BMI body mass index, EPO erythropoietin, Ft ferritin, Fe iron, Hgb hemoglobin, sTfR soluble transferrin
receptor, Tf transferrin, CRP C-reactive protein
a Values are means ± standard deviation (SD)
bValues are median and interquartile range (25th–75th percentiles)
c Values are percentage
Hepcidin in Pregnancy: Correlation with Smoking 17
hepcidin level and inflammatory markers during pregnancy
was recognized; also our findings are in accordance with these
results [1, 25, 31]. Although in both studied group (non-
smoking and smoking pregnant women), the C-reactive pro-
tein concentrations were slightly higher than in non-pregnant
women, it was in the range of gestational age-specific refer-
ence values [5]. Similar to Rehu et al. [30] and Young et al.
[26], we measured hepcidin in serum of healthy, non-anemic
women using ELISA method which directly detects the bio-
logically active 25-amino-acid form of this hormone. It is
noteworthy that we conducted our study toward the end of
the pregnancy and 90 % of births took place vaginally.
To our knowledge, this is the first study to report influence
of tobacco smoking on hepcidin in blood of pregnant women.
Previously, we observed a negative effect of smoking on se-
rum pro-hepcidin (pro-hormone) levels during gestation [33].
A recent analysis showed a significant inverse association
between hepcidin concentrations and the number of cigarettes
per day as well as cotinine levels. Our results confirmed re-
ports observed in groups of non-smoking women regarding
the positive association between hepcidin and ferritin as well
as hemoglobin during gestation [2, 26–28]. In agreement with
Finkenstead et al. [29], also a negative relation between
hepcidin and erythropoietin was found. We suggested that
accompanying smoking hypoxia can suppress hepcidin
mRNA expression reducing this hormone in mothers and
probably in newborns. The higher erythropoietin concentra-
tion (as indicator of hypoxia) coexisting with lower iron and
hemoglobin levels in smoking pregnant women and correla-
tion between this parameter and smoking dose-dependent
hepcidin concentration seem to confirm this hypothesis.
As noted in the introduction, hypoxia in smoking people
affects not only increased deficiency of iron for erythropoiesis
but also oxidative damage depending on the amount of en-
hanced reactive oxygen species (ROS) generated by tobacco
smoke. It is widely accepted that in cigarette smokers, in-
creased oxidative stress is observed, concerning smoking
pregnant women [34]. There have been a few in vivo trials
documenting the effects of hypoxia on circulating hepcidin
level, with only four of those focusing on human. The de-
creased concentration of this hormone in chronic obstructive
pulmonary disease (CODP) patients and in healthy volunteers
exposed to hypobaric hypoxia at high altitude was observed
[35, 36]. The remaining two suggested that prenatal, utero-
placental chronic hypoxia reduced pro-hepcidin synthesis in
the fetus [37, 38]. Animal models demonstrate that increasing
Table 2 Univariate regression analyses of hepcidin with number of
cigarettes per day, serum cotinine concentration, and studied
biochemical markers in smoking pregnant women (n = 41)
Independent variables β SE for β p value R2 %
Number of cigarettes/day −0.46 0.142 0.002 21.5
Cotinine −0.38 0.148 0.014 14.5
EPO −0.25 0.109 0.027 6.1
Ft 0.47 0.099 0.000 22.5
Fe 0.21 0.010 0.054 4.5
Hgb 0.27 0.108 0.015 7.2
sTfR −0.25 0.109 0.024 6.2
Tf −0.17 0.111 0.128 2.9
CRP 0.14 0.159 0.399 1.8
EPO erythropoietin, Ft ferritin, Fe iron, Hgb hemoglobin, sTfR soluble
transferrin receptor, Tf transferrin, CRP C-reactive protein
Table 3 Simple correlations
(Spearman or Pearson) between
newborn anthropometric
parameters and the concentrations
of studied biochemical
parameters in group of smoking
(n = 41) and non-smoking
(n = 40) pregnant women





r p value r p value r p value r p value
Hepcidina 0.45 0.003 0.57 0.000 0.47 0.002 0.42 0.008
EPOb −0.21 0.180 −0.10 0.557 −0.42 0.007 −0.06 0.718
sTf a −0.13 0.427 −0.06 0.708 −0.22 0.175 0.03 0.849
Tfa 0.07 0.685 −0.25 0.117 −0.07 0.659 −0.18 0.266
Ftb 0.22 0.163 0.30 0.064 0.19 0.233 −0.01 0.967
Fea 0.14 0.393 0.31 0.049 0.20 0.205 0.13 0.420
Hgba −0.09 0.561 0.32 0.042 0.07 0.669 0.24 0.134
Cotinineb −0.61 0.000 – – −0.37 0.017 – –
Number of cigarettes/dayb −0.54 0.000 – – −0.32 0.039 – –
EPO erythropoietin, sTfR soluble transferrin receptor, Tf transferrin, Ft Ferritin, Fe iron, Hgb hemoglobin
a Pearson correlation
b Spearman correlation
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reactive oxygen species, especially H2O2, reduced ex-
pression of hepcidin mRNA as well as hepatic iron
concentration [39, 40]. However, iron, inflammation,
and smoking are also known to drive ROS production,
so the interaction of these factors is complex and it is
likely to be a balance of all this factors that regulates
the final level of hepcidin synthesis in human. There-
fore, it is possible that oxidative stress may attenuate
the iron and inflammation-induced upregulation of
hepcidin, which would lead to a relative lowering of
hepcidin and elevated iron absorption [11, 39].
There is a strong evidence that smoking during preg-
nancy influenced negatively on birth body weight,
length, and head circumference [41–43]. Also, maternal
iron deficiency anemia (IDA) has been linked to higher
risk of low birth, but the detailed mechanisms by which
this occurs still remain unclear [44–46]. Hepcidin is
involved in active transport of iron through placental
syncytiothrophoblast from mother to child. The findings
of Young and colleagues [26] indicated that maternal
hepcidin at least in part determined fetal iron homeosta-
sis. They showed inverse correlation between maternal
hepcidin and the iron transport to the fetus [26]. There
have been no studies that describe association between
maternal concentrations of hepcidin and birth anthropo-
metric parameters. Some authors reported that cord
blood hepcidin level is similar in full-term intrauterine
growth-restricted and appropriate-for-gestational-age in-
fants at birth [9]. However, maternal hepcidin concen-
tration was not associated with cord blood hepcidin in a
newborn at term [30]. We found that maternal hepcidin
could be an important predictor of birth weight and
length of full-term newborns in tobacco abstinent as
well as in smoking. Maternal smoking is associated
with increased fetal iron requirements and stimulates
fetal erythropoiesis depending on the degree of exposure
to tobacco smoke [16, 46, 47]. Maternal low level of
hepcidin and negative iron balance may lead to intra-
uterine growth retardation as well as low birth weight
[9, 30, 45]. Further studies may explain the mechanism
by which downregulation of hepcidin by tobacco
smoking hypoxia contributes to fetal growth.
Our study is limited by its relatively small sample size;
however, both studied groups were similar for ethnicity, ges-
tational age, fetal gender, and type of birth which are recog-
nized as important factors for hepcidin levels [1, 30, 32, 48].
Additionally, we did not measure iron dietary intake, which
might influence markers of iron metabolism, but our popula-
tion consisted of healthy, well-nourished mothers remaining
on a mixed diet and receiving regular multivitamin prepara-
tion (containing small doses of iron and folic acid) as a part of
routine perinatal care. Another limitation is that we have not
studied direct effect of tobacco smoking on newborn iron
metabolism, and future research should assess maternal and
cord blood hepcidin level in a large group of matched mater-
nal cord pairs.
In conclusion, tobacco smoking affected hepcidin level in
serum of pregnant women in a dose-dependent manner. Low
concentrations of iron and hemoglobin in maternal serum
coexisting with high level of erythropoietin suggest that
smoking could lead to subclinical iron deficiency and chronic
hypoxia not only in mothers but also in fetus. Low serum
hepcidin concentration in smoking pregnant women might
be associated with lower fetal birth weight and length.
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